Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Prelude Therapeutics stock | $31

Own Prelude Therapeutics stock in just a few minutes.

Updated . What changed?

Fact checked

Prelude Therapeutics Inc is a biotechnology business based in the US. Prelude Therapeutics shares (PRLD) are listed on the NASDAQ and all prices are listed in US Dollars. Prelude Therapeutics employs 51 staff and has a market cap (total outstanding shares value) of USD$1.4 billion.

How to buy shares in Prelude Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Prelude Therapeutics. Find the stock by name or ticker symbol: PRLD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Prelude Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$31, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Prelude Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Prelude Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Prelude Therapeutics share price

Use our graph to track the performance of PRLD stocks over time.

Prelude Therapeutics shares at a glance

Information last updated 2020-10-19.
Latest market closeUSD$31
52-week rangeUSD$23.693 - USD$50.19
50-day moving average USD$35.5463
200-day moving average USD$35.5463
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Prelude Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Prelude Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Prelude Therapeutics price performance over time

Historical closes compared with the close of $31 from 2020-10-16

1 week (2021-01-08) -53.36%
1 month (2020-12-15) -55.66%
3 months (2020-10-15) -8.85%
6 months (2020-07-11) N/A
1 year (2020-01-11) N/A
2 years (2019-01-11) N/A
3 years (2018-01-11) N/A
5 years (2016-01-11) N/A

Prelude Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$1.4 billion

TTM: trailing 12 months

Shorting Prelude Therapeutics shares

There are currently 5,757 Prelude Therapeutics shares held short by investors – that's known as Prelude Therapeutics's "short interest". This figure is up from 0 last month.

There are a few different ways that this level of interest in shorting Prelude Therapeutics shares can be evaluated.

Prelude Therapeutics's "short interest ratio" (SIR)

Prelude Therapeutics's "short interest ratio" (SIR) is the quantity of Prelude Therapeutics shares currently shorted divided by the average quantity of Prelude Therapeutics shares traded daily (recently around 575700). Prelude Therapeutics's SIR currently stands at 0.01. In other words for every 100,000 Prelude Therapeutics shares traded daily on the market, roughly 10 shares are currently held short.

To gain some more context, you can compare Prelude Therapeutics's short interest ratio against those of similar companies.

However Prelude Therapeutics's short interest can also be evaluated against the total number of Prelude Therapeutics shares, or, against the total number of tradable Prelude Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prelude Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Prelude Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Prelude Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Prelude Therapeutics.

Find out more about how you can short Prelude Therapeutics stock.

Prelude Therapeutics share dividends

We're not expecting Prelude Therapeutics to pay a dividend over the next 12 months.

Prelude Therapeutics overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site